Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.990
-0.130 (-4.17%)
Sep 9, 2026, 4:00 PM EDT - Market closed
Perspective Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jun '22 Jun 30, 2022 |
| 0.41 | 0.88 | 1.45 | 1.43 | 5.42 | - | |
Revenue Growth | -66.88% | -39.20% | 1.40% | -73.52% | -46.13% | - |
Cost of Revenue | 96.18 | 84.22 | 41.64 | 20.34 | 3.05 | - |
Gross Profit | -95.77 | -83.33 | -40.18 | -18.91 | 2.37 | - |
Selling, General & Admin | 29.46 | 30.23 | 26.61 | 21.06 | 9.35 | 5.57 |
Research & Development | - | - | - | 0.97 | 1.81 | 0.85 |
Operating Expenses | 29.46 | 30.23 | 26.61 | 22.03 | 11.17 | 6.42 |
Operating Income | -125.23 | -113.56 | -66.8 | -40.94 | -8.8 | -6.42 |
Interest Expense | -0.31 | -0.38 | -0.05 | -0.08 | - | - |
Interest & Investment Income | 8.12 | 8.11 | 10.52 | 0.93 | 0.62 | 0.12 |
Earnings From Equity Investments | -0 | -0 | -0.01 | -0.02 | - | - |
Other Non Operating Income (Expenses) | - | 1.4 | - | - | - | - |
EBT Excluding Unusual Items | -117.42 | -104.43 | -56.34 | -40.11 | -8.18 | -6.3 |
Impairment of Goodwill | - | - | -24.06 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0.03 | - | -0.31 | - |
Pretax Income | -117.42 | -104.43 | -80.43 | -40.11 | -8.49 | -6.3 |
Income Tax Expense | -0.79 | -0.79 | -2.1 | -2.65 | - | - |
Earnings From Continuing Operations | -116.63 | -103.64 | -78.33 | -37.46 | -8.49 | -6.3 |
Earnings From Discontinued Operations | 0.2 | 0.51 | -0.95 | -9.05 | -2.28 | -0.97 |
Net Income | -116.43 | -103.12 | -79.28 | -46.51 | -10.76 | -7.27 |
Net Income to Common | -116.43 | -103.12 | -79.28 | -46.51 | -10.76 | -7.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 93 | 74 | 64 | 27 | 14 | 14 |
Shares Outstanding (Diluted) | 93 | 74 | 64 | 27 | 14 | 14 |
Shares Change | 29.45% | 14.57% | 140.72% | 88.38% | 0.06% | 36.73% |
EPS (Basic) | -1.25 | -1.40 | -1.23 | -1.74 | -0.76 | -0.51 |
EPS (Diluted) | -1.25 | -1.40 | -1.23 | -1.74 | -0.76 | -0.51 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -121.19 | -95.23 | -72.71 | -37.99 | -10.68 | -7.98 |
Free Cash Flow Per Share | -1.30 | -1.29 | -1.13 | -1.42 | -0.75 | -0.56 |
Gross Margin | - | - | - | - | 43.71% | - |
Operating Margin | -30619.07% | -12846.61% | -4594.02% | -2855.02% | -162.47% | - |
Profit Margin | -28467.97% | -11665.27% | -5452.48% | -3243.24% | -198.71% | - |
Free Cash Flow Margin | -29630.07% | -10772.96% | -5000.55% | -2648.88% | -197.28% | - |
EBITDA | -121.19 | -110.32 | -64.5 | -40.23 | -8.48 | -6.14 |
EBITDA Margin | - | - | - | - | -156.56% | - |
D&A For EBITDA | 4.05 | 3.24 | 2.3 | 0.71 | 0.32 | 0.28 |
EBIT | -125.23 | -113.56 | -66.8 | -40.94 | -8.8 | -6.42 |
EBIT Margin | - | - | - | - | -162.47% | - |
Revenue as Reported | - | - | - | - | 5.42 | - |